Phathom Pharmaceuticals, Inc.

PHAT

US71722W1071

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
10.41 ^USD	+0.19%		+3.07%	+14.02%

May. 09	Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Phathom Pharmaceuticals, Inc. Announces the Demise of Tachi Yamada as Chairman of the Company

August 05, 2021 at 07:30 am EDT

Phathom Pharmaceuticals, Inc. announced that its chairman and founder, Dr. Tachi Yamada, passed away suddenly at his Seattle, Washington home on August 4, 2021.

Latest news about Phathom Pharmaceuticals, Inc.

Transcript : Phathom Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Stifel Starts Phathom Pharmaceuticals With Buy Rating, $24 Price Target	May. 03	MT
Transcript : Phathom Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 07, 2024	Mar. 07
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Phathom Pharmaceuticals Announces Voquezna® Tablets for Erosive Gerd and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients	Feb. 13	CI
Needham Raises Price Target on Phathom Pharmaceuticals to $26 From $23, Maintains Buy Rating	Jan. 05	MT
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) dropped from S&P Pharmaceuticals Select Industry Index	Dec. 18	CI
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD	Dec. 06	CI
Phathom Pharmaceuticals Says Erosive GERD Treatment Voquenza Commercially Available in US	Nov. 28	MT
Phathom Pharmaceuticals, Inc. Announces Commercial Availability of VOQUEZNA®? Tablets	Nov. 28	CI
Phathom Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Phathom Pharmaceuticals Insider Sold Shares Worth $110,871, According to a Recent SEC Filing	Nov. 03	MT
Goldman Sachs Adjusts Price Target on Phathom Pharmaceuticals to $10 From $9, Maintains Neutral Rating	Nov. 03	MT
Transcript : Phathom Pharmaceuticals, Inc. - Special Call	Nov. 02
Phathom Pharmaceuticals Gets FDA Approval for Voquezna Treatment	Nov. 01	DJ
Phathom Pharmaceuticals, Inc. Announces FDA Approval of VOQUEZNA® Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults	Nov. 01	CI
Phathom Pharmaceuticals Says US FDA Approves Reformulation of Vonoprazan Tablets for Helicobacter Pylori Infection	23-10-30	MT
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for Voquezna Triple Pak (Vonoprazan, Amoxicillin, Clarithromycin) and Voquezna Dual Pak (Vonoprazan, Amoxicillin) for the Treatment of H. Pylori Infection in Adults	23-10-30	CI
Phathom Pharmaceuticals Seeks FDA Nod for Vonoprazan to Treat Non-Erosive GERD in Adults	23-09-26	MT
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive Germany	23-09-26	CI
Phathom Pharmaceuticals, Inc.(NasdaqGS:PHAT) added to S&P Pharmaceuticals Select Industry Index	23-09-18	CI
Sector Update: Health Care Stocks Gaining Late Afternoon	23-08-21	MT
Sector Update: Health Care	23-08-21	MT

Chart Phathom Pharmaceuticals, Inc.

Duration

Period

More charts

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Companyâs pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Phathom Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.41 USD

Average target price

22.29 USD

Spread / Average Target

+114.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHATHOM PHARMACEUTICALS, INC.	+14.02%	609M
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+50.24%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.01%	12.1B

Other Biotechnology & Medical Research